51 related articles for article (PubMed ID: 25434441)
1. A clinical therapeutic protein drug-drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis.
Jang G; Kaufman A; Lee E; Hamilton L; Hutton S; Egbuna O; Padhi D
Pharmacol Res Perspect; 2014 Apr; 2(2):e00033. PubMed ID: 25505582
[TBL] [Abstract][Full Text] [Related]
2. Osteosclerosis induced by denosumab.
Kobayashi E; Setsu N
Lancet; 2015 Feb; 385(9967):539. PubMed ID: 25465110
[No Abstract] [Full Text] [Related]
3. New strategies for osteoporosis patients previously managed with strontium ranelate.
Vestergaard P
Ther Adv Musculoskelet Dis; 2014 Dec; 6(6):217-25. PubMed ID: 25435924
[TBL] [Abstract][Full Text] [Related]
4. Severe hypocalcemia following denosumab injection in a hemodialysis patient.
McCormick BB; Davis J; Burns KD
Am J Kidney Dis; 2012 Oct; 60(4):626-8. PubMed ID: 22854051
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
6. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency.
Ungprasert P; Cheungpasitporn W; Srivali N; Kittanamongkolchai W; Bischof EF
Am J Emerg Med; 2013 Apr; 31(4):756.e1-2. PubMed ID: 23399342
[TBL] [Abstract][Full Text] [Related]
7. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
[TBL] [Abstract][Full Text] [Related]
8. [Denosumab for bone metastasis of thoracic tumors-preparation of a practice manual and evaluation of its effectiveness].
Kondo Y; Tamiya M; Hirashima T; Ryota N; Sando M; Iwata K; Okamoto N; Suzuki H; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Tsuboi T; Yamato A; Shimura K; Kawase I
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1391-5. PubMed ID: 25434441
[TBL] [Abstract][Full Text] [Related]
9. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
[TBL] [Abstract][Full Text] [Related]
10. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
11. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
Lipton A; Balakumaran A
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
